Forkhead box protein P3 (FOXP3) (FOXP3)

Forkhead box protein P3 (FOXP3) is a master transcription factor belonging to the forkhead/winged-helix family that is essential for the development and suppressive function of T regulatory (Treg) cells (UniProt P0C6P5). It acts as a key orchestrator of immune homeostasis by repressing the production of pro-inflammatory cytokines and controlling the expression of genes involved in lymphocyte suppression (PubMed: 12522256). In humans, mutations in the FOXP3 gene result in IPEX syndrome, a severe and often fatal autoimmune condition characterized by polyendocrinopathy and enteropathy (StatPearls: IPEX Syndrome). Within the tumor microenvironment, FOXP3+ Tregs frequently accumulate and suppress anti-tumor immunity, allowing tumors to evade the host immune system (Nature Immunology, 2007). Although FOXP3 is an intracellular protein and traditionally considered 'undruggable' by small molecules, it is currently a focus of advanced therapeutic strategies including antisense oligonucleotides like AZD8701 and inhibitory peptides. Clinical approaches also include the use of monoclonal antibodies to deplete FOXP3-expressing cells in cancer or recombinant cytokines to expand them in autoimmune settings. The primary therapeutic challenge remains achieving cell-type specificity to avoid inducing widespread systemic autoimmunity while successfully modulating the targeted immune response.

Other names

FOXP3ScurfinForkhead box P3IPEXJM2XPIDAIIDPIDSAForkhead box protein P3 positive T regulatory cells

FOXP3 is primarily targeted through antisense oligonucleotides (e.g., AZD8701) designed to reduce mRNA expression, or via synthetic peptides (e.g., P60) that inhibit its nuclear translocation and transcriptional activity. Additionally, the FOXP3+ T regulatory cell population is modulated indirectly through antibodies targeting surface receptors like CTLA-4 (to deplete Tregs) or IL-2 receptors (to either deplete or expand Tregs depending on the clinical context).